Vidya H Veldore1, Shekar Patil2, Shilpa Prabhudesai3, C T Satheesh2, H P Shashidhara2, Naveen Krishnamoorthy3, D Hazarika3, R Tejaswi3, Ankita Prabhudev3, Radheshyam Naik2, Raghavendra M Rao2,4, B S Ajai Kumar3,2,4. 1. Triesta Reference Laboratory, Triesta Sciences, A Unit of Health Care Global Enterprises Ltd., 8, P Kalinga Rao Road, HCG Tower 1, SR Nagar, Bangalore, 560 027, India. vidya.veldore@gmail.com. 2. HCG Oncology Hospitals, Bangalore, India. 3. Triesta Reference Laboratory, Triesta Sciences, A Unit of Health Care Global Enterprises Ltd., 8, P Kalinga Rao Road, HCG Tower 1, SR Nagar, Bangalore, 560 027, India. 4. Centre for Academics and Research, HCG Foundation, Bangalore, 560 027, India.
Abstract
BACKGROUND: Although biopsy is the gold standard for diagnosis, cytological material has often been used to assist in making a pathologic diagnosis as well as for molecular testing in certain cancers such as in the lung, cervix, and head/neck. OBJECTIVE: Our objective is to share experience from our institution in the use of cytological material in screening for epidermal growth factor receptor (EGFR) mutations in a subset of patients with non-small cell lung cancer (NSCLC). METHODS: Fine needle aspirates, pleural effusion, cell blocks of 223 NSCLC patients, where cytology suggested malignancy were screened for EGFR mutation in exons 18-21 using Scorpion(®) ARMS real-time polymerase chain reaction (PCR) technology. RESULTS: Overall, EGFR mutation was seen in 43.5 % of study samples. Deletions were highest in exon 19 (27.2 %), followed by exon 21 (15.5 %), exon 18 (5.3 %), and exon 20 (1.9 %). Chi-squared analysis revealed a significant correlation for mutation status in women compared with men (χ (2) = 5.88, p = 0.02), with exon 19 mutation predominating (χ (2) = 5.66, p = 0.02). CONCLUSION: Our results demonstrate the successful use of cytology material for molecular testing in a subset of NSCLC patients to direct their treatment.
BACKGROUND: Although biopsy is the gold standard for diagnosis, cytological material has often been used to assist in making a pathologic diagnosis as well as for molecular testing in certain cancers such as in the lung, cervix, and head/neck. OBJECTIVE: Our objective is to share experience from our institution in the use of cytological material in screening for epidermal growth factor receptor (EGFR) mutations in a subset of patients with non-small cell lung cancer (NSCLC). METHODS: Fine needle aspirates, pleural effusion, cell blocks of 223 NSCLCpatients, where cytology suggested malignancy were screened for EGFR mutation in exons 18-21 using Scorpion(®) ARMS real-time polymerase chain reaction (PCR) technology. RESULTS: Overall, EGFR mutation was seen in 43.5 % of study samples. Deletions were highest in exon 19 (27.2 %), followed by exon 21 (15.5 %), exon 18 (5.3 %), and exon 20 (1.9 %). Chi-squared analysis revealed a significant correlation for mutation status in women compared with men (χ (2) = 5.88, p = 0.02), with exon 19 mutation predominating (χ (2) = 5.66, p = 0.02). CONCLUSION: Our results demonstrate the successful use of cytology material for molecular testing in a subset of NSCLCpatients to direct their treatment.
Authors: Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2015-02-04 Impact factor: 508.702
Authors: Hee Joung Kim; Seo Young Oh; Wan Seop Kim; Sun Jong Kim; Gwang Ha Yoo; Won Dong Kim; Kye Young Lee Journal: Oncol Lett Date: 2012-10-01 Impact factor: 2.967
Authors: P M Parikh; A A Ranade; Babu Govind; N Ghadyalpatil; R Singh; R Bharath; G S Bhattacharyya; S Koyande; M Singhal; A Vora; A Verma; S Hingmire Journal: South Asian J Cancer Date: 2016 Jul-Sep